Exhibit 14-2

Of an estimated 5.4 million U.S. CGM users as of May 2026 (Please see Exhibit 14-1 Dexcom, 2026 Investor Day Presentation (May 14, 2026) at 38 (assuming mid-points for the ranges provided)), Edgepark's unique CGM patient base is approximately [redacted] representing approximately [redacted] of all CGM users. Adapt's CGM patient base is approximately [redacted] in 2025, representing less than [redacted] of all CGM users. The parties' estimated combined share is therefore [redacted].